Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 10:07 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 82 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Tysabri Clear all
Completed Phase 4 Interventional

Natalizumab Temporary Discontinuation Study

NCT02775110
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Natalizumab discontinuation
Other
Lead sponsor
University at Buffalo
Other
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
2
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated May 17, 2016 · Synced Oct 21, 2026, 10:07 AM EDT
Completed No phase listed Observational

Tysabri Observational Cohort Study - Multiple Sclerosis (MS) Registries

NCT03399981
View directory record Official record
Conditions
Progressive Multifocal Leukoencephalopathy
Interventions
Tysabri
Biological
Lead sponsor
Biogen
Industry
Eligibility
Not listed
Enrollment
80,327 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 19, 2024 · Synced Oct 21, 2026, 10:07 AM EDT
Completed No phase listed Observational

JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab

NCT01070836
View directory record Official record
Conditions
Relapsing Multiple Sclerosis
Interventions
natalizumab
Drug
Lead sponsor
Biogen
Industry
Eligibility
Not listed
Enrollment
35,895 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
473
States / cities
Birmingham, Alabama • Cullman, Alabama • Tucaloosa, Alabama + 386 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2016 · Synced Oct 21, 2026, 10:07 AM EDT
Withdrawn Phase 2 Interventional

Alternative Treatment Paradigm for Natalizumab Trial

NCT01710228
View directory record Official record
Conditions
Multiple Sclerosis (MS)
Interventions
methylprednisolone
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 29, 2016 · Synced Oct 21, 2026, 10:07 AM EDT
Withdrawn Not applicable Interventional

Sensation, Motion, and Quality of Life on Natalizumab and Off Natalizumab

NCT05172466
View directory record Official record
Conditions
Relapsing-remitting Multiple Sclerosis (RRMS)
Interventions
BeCare application
Device
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 25, 2022 · Synced Oct 21, 2026, 10:07 AM EDT
Completed Phase 2 Interventional Results available

Phase 2 Efficacy, Safety, and Tolerability Study of Natalizumab in Focal Epilepsy

NCT03283371
View directory record Official record
Conditions
Epilepsy, Focal Seizures, Partial Seizures
Interventions
Natalizumab, Placebo
Drug · Other
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 75 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
31
States / cities
Birmingham, Alabama • Phoenix, Arizona • San Diego, California + 26 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2021 · Synced Oct 21, 2026, 10:07 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Does Long-Term Natalizumab (NTZ) Therapy Normalize Brain Atrophy Rates and Quality of Life (QOL) in Relapsing Remitting Multiple Sclerosis (RRMS)?

NCT02588053
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 55 Years
Enrollment
85 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2019
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 17, 2019 · Synced Oct 21, 2026, 10:07 AM EDT
Completed Phase 3 Interventional

A Clinical Trial of Natalizumab in Individuals With Moderately to Severely Active Crohn's Disease

NCT00078611
View directory record Official record
Conditions
Crohn's Disease
Interventions
natalizumab
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
462 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
63
States / cities
Oro Valley, Arizona • Tucson, Arizona • Anaheim, California + 54 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2016 · Synced Oct 21, 2026, 10:07 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy of Natalizumab in Combination With Remicade in the Treatment of Crohn's Disease

NCT00055536
View directory record Official record
Conditions
Crohn's Disease
Interventions
natalizumab
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
18
States / cities
Gainesville, Florida • Jacksonville, Florida • Atlanta, Georgia + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2016 · Synced Oct 21, 2026, 10:07 AM EDT
Completed Phase 3 Interventional

Safety and Efficacy of Natalizumab in the Treatment of Multiple Sclerosis

NCT00027300
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Natalizumab, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 50 Years
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
14
States / cities
Scottsdale, Arizona • Berkeley, California • Davis, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2017 · Synced Oct 21, 2026, 10:07 AM EDT
Terminated Phase 3 Interventional Results available

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis

NCT01416181
View directory record Official record
Conditions
Secondary Progressive Multiple Sclerosis
Interventions
natalizumab, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 58 Years
Enrollment
889 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
35
States / cities
Phoenix, Arizona • Tucson, Arizona • Fullerton, California + 29 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2017 · Synced Oct 21, 2026, 10:07 AM EDT
Completed No phase listed Observational

Pregnancy Exposure Registry for Tysabri®

NCT00472992
View directory record Official record
Conditions
Crohn's Disease, Prenatal Exposure, Multiple Sclerosis, Pregnancy
Interventions
Not listed
Lead sponsor
Biogen
Industry
Eligibility
Female only
Enrollment
376 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Aug 11, 2014 · Synced Oct 21, 2026, 10:07 AM EDT
Terminated No phase listed Observational

Efficacy of COVID-19 Vaccination in Patients With Multiple Sclerosis Treated With Immune Modulating Medication

NCT04796584
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Analysis of cell-mediated and antibody-mediated immunity to SARS-CoV-2 virus
Other
Lead sponsor
Providence Health & Services
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 3, 2023 · Synced Oct 21, 2026, 10:07 AM EDT
Completed Phase 2 Interventional

Safety, Tolerability and Effectiveness of Natalizumab in Adolescents With Active Crohn's Disease

NCT00055367
View directory record Official record
Conditions
Crohn's Disease
Interventions
natalizumab
Drug
Lead sponsor
Biogen
Industry
Eligibility
12 Years to 17 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
11
States / cities
Los Angeles, California • Hartford, Connecticut • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2016 · Synced Oct 21, 2026, 10:07 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Humoral and T-Cell Responses to COVID-19 Vaccination in Multiple Sclerosis Patients Treated With Ocrelizumab Treated With Ocrelizumab or Natalizumab

NCT04837651
View directory record Official record
Conditions
Multiple Sclerosis, Demyelinating Autoimmune Diseases, CNS, Autoimmune Diseases of the Nervous System, Nervous System Diseases, Demyelinating Diseases, Autoimmune Diseases, Immune System Diseases, Pathologic Processes
Interventions
Elecsys semi-quantitative Anti-SARS-CoV-2 antibody test, T-Detect COVID T-cell blood test
Device
Lead sponsor
Dragonfly Research, LLC
Other
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Wellesley, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 2, 2021 · Synced Oct 21, 2026, 10:07 AM EDT
Terminated No phase listed Observational

CD INFORM: Investigating Natalizumab Through Further Observational Research and Monitoring

NCT00707512
View directory record Official record
Conditions
Crohn's Disease
Interventions
natalizumab
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
35
States / cities
Scottsdale, Arizona • Oceanside, California • San Francisco, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2024 · Synced Oct 21, 2026, 10:07 AM EDT
Completed No phase listed Observational

Risk Perception in Multiple Sclerosis

NCT05528666
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
High Efficacy Therapy (HET), Non High Efficacy Therapy (Non-HET)
Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
4,361 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 8, 2022 · Synced Oct 21, 2026, 10:07 AM EDT
Completed No phase listed Observational

TYSABRI Global Observational Program in Safety

NCT00477113
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Not listed
Lead sponsor
Biogen
Industry
Eligibility
Not listed
Enrollment
2,207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 22, 2015 · Synced Oct 21, 2026, 10:07 AM EDT
Active, not recruiting Phase 4 Interventional

Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS

NCT03535298
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Early Highly Effective Therapies Group, Escalation Therapies Group
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 60 Years
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
15
States / cities
Aurora, Colorado • Minneapolis, Minnesota • Rochester, Minnesota + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 21, 2026, 10:07 AM EDT
Completed No phase listed Observational

JC Virus Reactivation in Multiple Sclerosis

NCT02004444
View directory record Official record
Conditions
Progressive Multifocal Leukoencephalopathy, Multiple Sclerosis
Interventions
Not listed
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 29, 2016 · Synced Oct 21, 2026, 10:07 AM EDT
Completed Phase 2 Interventional Results available

Multicenter Study Of Natalizumab Plus Standard Steroid Treatment For High Risk Acute Graft-Versus-Host Disease

NCT02133924
View directory record Official record
Conditions
Acute Graft Versus Host Disease
Interventions
natalizumab, steroids
Drug
Lead sponsor
John Levine
Other
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
12
States / cities
Duarte, California • Atlanta, Georgia • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2022 · Synced Oct 21, 2026, 10:07 AM EDT
Completed Phase 4 Interventional Results available

Sequential Natalizumab - Alemtuzumab Therapy in Patients With Relapsing Forms of Multiple Sclerosis

NCT03135249
View directory record Official record
Conditions
Multiple Sclerosis (MS)
Interventions
Alemtuzumab
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 60 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
2
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 15, 2022 · Synced Oct 21, 2026, 10:07 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Impact of Natalizumab Versus Fingolimod in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants

NCT02342704
View directory record Official record
Conditions
Relapsing-Remitting Multiple Sclerosis
Interventions
natalizumab, fingolimod
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 60 Years
Enrollment
111 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
12
States / cities
Aurora, Colorado • Colorado Springs, Colorado • Port Charlotte, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2017 · Synced Oct 21, 2026, 10:07 AM EDT
Completed Phase 3 Interventional Results available

Natalizumab Re-Initiation of Dosing

NCT00306592
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
BG00002 (natalizumab)
Biological
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
404 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
53
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 46 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2017 · Synced Oct 21, 2026, 10:07 AM EDT